After more than 20 years, Novartis has finally decided to sell its substantial share in fellow Swiss pharma group Roche for $20.7 billion, a decent return on its original $5 billion investm
Rocketing sales of COVID-19 vaccine Comirnaty have allowed Pfizer to raise its full-year forecasts for the shot once again to a whopping $36 billion, more than double its predictions just a
President Joe Biden has jettisoned a raft of policy proposals aimed at curbing the price of prescription medicines as part of the US administration's $1.75 trillion 'build back better' fram
Novartis revealed today that it may consider divesting its generic medicines subsidiary Sandoz – amongst other options – which would further narrow its focus to innovative medicines.
Activist investors are pushing back against Merck & Co's recent $11.5 billion deal to acquire Acceleron Pharma, arguing that its $180-per-share offer seriously undervalues the company.
Analysts were predicting sales of Biogen's recently approved Alzheimer's therapy Aduhelm may start to gather a little momentum in the third quarter, but the drug seems to be going into reve
Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially.